Extended Data Table 3 Measurable residual disease and cytogenetic responses

From: The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

  1. *MRD, minimal or measurable residual disease assessed at participating sites by multicolor flow cytometry or by polymerase chain reaction. MRD status percentage is based on patients with non-missing MRD status out of the responders. MRD-negative rates are shown as n (%).
  2. †CCyR denotes complete cytogenetic remission in which KMT2A fusions were not detectable by fluorescence in situ hybridization in evaluable patients assessed at participating sites.
  3. CR, complete remission; CRh, complete remission with partial haematologic recovery; CRi, complete remission with incomplete haematologic recovery; CRp, complete remission with incomplete platelet recovery; FISH, fluorescence in situ hybridization; MLFS, morphologic leukaemia free state; MRD, minimal or measurable residual disease; NA, not applicable given absence of disease defining cytogenetic abnormalities.
Back to article page